

# ANDROGEN HORMONE LEVELS IN WOMEN WITH MALE PATTERN BALDNESS

N. Martinović, J. Micić, S. Ivanović and A. Krunić

## ABSTRACT

*Background* Androgen hormones in women with androgenetic alopecia (AA) were studied.

*Materials and methods.* The prospective study included 50 women with androgenetic alopecia in fertile age. Blood and urine were taken on the 7th and 21st day of the same menstrual cycle. Free testosterone (T), androstenediol (A-DIOL) and dehydroepiandrosterone (DHA) were assayed in serum. In the 24-hour urine T, DHA, androsterone (A), etiocholanolone (E) and 17-ketosteroid (17-KS) levels were monitored. *Results.* Statistical deviation from physiological levels was observed for serum T.

*Conclusion.* It is suggested that A-DIOL was possibly the principal androgen in etiopathogenesis of AA in women. The hormonal disorder seems to be expressed in the estrogen phase of the menstrual cycle.

## KEY WORDS

*alopecia, androgenetic, testosterone, androgen fractions, female sex*

---

## INTRODUCTION

The studies of metabolism and mechanisms of androgen action on the hair follicle as one of significant target units of androgenetic steroids have not significantly contributed to the solution of the basic dilemma: why and how do androgenetic hormones cause hair follicle involution constantly in the same regions of capillitium which are predisposed for androgenetic alopecia (AA), without disturbing the follicle function in the remaining regions? Neither

do in vitro study methods (incubation of isolated hair roots with particular androgens and determination of metabolite concentration in incubates or fibroblast culture as a model of studying the androgen binding capacity by the skin) enable an exact insight into complex metabolic and biological processes induced by androgen steroids.

Special challenge in AA in women is due to the specificity of general hormonal milieu and to the fact that alopecia nevertheless represents stigmata of certain degree of androgenization<sup>1</sup>. This high incidence of AA in women is puzzling. Some authors

indicate the existence of metabolic disorders already on secretory level in women with AA<sup>2,4</sup>, while others assume an androgen metabolic disorder on cellular effector level<sup>5-13</sup>. Although it has been proven that hair follicles possess enzymatic systems for metabolizing individual androgen steroids, metabolism is directed towards  $\alpha$ -metabolic route.

## MATERIALS AND METHODS

The purpose of the investigation was to study the levels of relevant androgen hormones in women with AA. The prospective study included 50 women in fertile age (Figure 1.) in whom AA was diagnosed: Ludwig I type in 42% and Ludwig II type in 58% according to Ludwig's classification<sup>18</sup>. The study included female subjects without clinical signs of hirsutism in whom by gynecological examination an ovarian organic disease was excluded, and who did not receive oral hormonal contraceptives<sup>19-24</sup>.

The quantitative analysis of relevant hormones (free testosterone /T/, androstenedione /A-DIOL/, dehydroepiandrosterone /DHA/ in serum and DHA,




Figure 1. Age distribution of 50 females with androgenetic alopecia

androsterone /A/, etiocholanolone /E/, 17-ketosteroids /17-KS/ in 24-hour urine) were performed by adsorption thin layer chromatography<sup>25</sup>. The material (blood

Table 1. Serum testosterone (T), dehydroepiandrosterone (DHA), androstenedione (A-DIOL) and urine dehydroepiandrosterone (DHA) levels in female patients with androgenetic alopecia type I and II (n = 50)

PARAMETERS	SERUM				URINE			
	[T] (ng%) (18 - 22)	[DHA] μg% (40 - 60)	[A-DIOL] μg% (20 - 40)	[DHA] (mg/24h) (1,5-2)				

day of period	7.	21.	7.	21.	7.	21.	7.	21.
x <sub>min</sub>	11	9,6	18	15	12	7	1,05	1,05
x <sub>max</sub>	60	37	105	100	72	90	5,52	3,62
x	26,1	23,4	48,6	52,6	31,8	33,4	2,01	1,98
SE <sub>x</sub>	11,0	7,9	18,5	20,6	15,2	16,2	0,84	0,58
KV%	41,6	33,5	37,6	39,3	47,2	48,3	41,1	29,1
r	0,12; NS		0,25; NS		0,60; p<0,01		0,44 p<0,05	
t	1.396; NS		1.011; NS		0.502; NS		0.206 NS	




Figure 2. Mean values of testosterone ( T ) in sera of 50 females with androgenetic alopecia. The samples were taken at day 7 and 21 of the same menstrual cycle




Figure 3. Mean values of dehydroepiandrosterone (DHA) in sera of 50 females with androgenetic alopecia. Samples were taken at day 7 and 21 of the same menstrual cycle




Figure 4. Mean values of androstenediol (A-DIOL) in sera of 50 females with androgenetic alopecia. Samples were taken at day 7 and 21 of the same menstrual cycle

samples in the morning biorhythm) and 24-hour urine were taken on the 7th and 21st day of the same menstrual cycle. The results of densitograms

were compared with physiological level parameters for women in reproductive period:

T 18-22 ng/dl, A-DIOL 20-40 µg/dl, DHA 40-60

Table 2. Dependence of dehydroepiandrosterone (DHA) and testosterone levels in the patients' sera

day	DHA (µg/dl)	decreased (≤ 17)		physiologic (18 - 22)		increased (≥ 23)		TOTAL	
		f	%	f	%	f	%	f	%
7th	decreased (≤ 39)	3	6	-	-	8	16	11	22
7th	physiologic (40 - 60)	6	12	10	20	12	24	28	56
7th	increased (≥ 61)	2	4	2	4	7	14	11	22
	TOTAL	11	22	12	24	27	54	50	100
21st	decreased (≤ 39)	4	8	2	4	8	16	14	28
21st	physiologic (40 - 60)	7	4	10	20	4	8	21	42
21st	increased (≥ 61)	1	12	4	8	10	20	15	30
	TOTAL	12	24	16	32	22	44	50	100

day 7 of the period:  $X^2 = 6.159$ ; NS

day 21 of the period:  $X^2 = 11.142$ ,  $p < 0.05$ ;  $c = 0.43$ ;  $p < 0.05$

µg/dl in serum and T 20-50 µg/dl, DHA 1.5 - 2 mg/24h, A 1-3 mg/24h, E 3-6 mg/24h and 17- KS 6 - 14 mg/24h in urine.

Since the literature data indicate the activities of  $\alpha$ -series, directing T metabolism towards A-DIOL in hair follicles in general, and particularly in regions predisposed to AA, the statistical analysis of results was directed towards correlative relationships: serum T  $\rightarrow$  A-DIOL, serum T  $\rightarrow$  DHA, serum DHA  $\rightarrow$  urine DHA. The outlined parameters were monitored particularly for the 7th and 21st days of the same menstrual cycle.

## STUDY RESULTS

The results of the statistical analysis of relevant steroids according to five-year age intervals showed that significant deviation from physiological levels was registered only for serum T (Figure 2). By F-test (variance analysis) it was evidenced that the female subjects' age did not influence either serum T levels or levels of other parameters. Thus, further analysis was performed for the female subject group as a

whole. Since the study was directed towards the a-metabolic route of steroids and elevated serum T levels were registered, further statistical analysis of results was directed towards serum T, DHA and A-DIOL levels and DHA in urine (Table 1, Figures 3, 4). Statistical analysis (C- coefficient of association) showed that there was a proven association of serum T levels for the 7th and 21st day of the cycle (C= 0.55,  $p < 0.01$ ). For serum T, DHA (Table 2) and A levels there were no significant differences found in average values on the 7th and 21st day of the cycle. For serum A-DIOL levels ( $p < 0.01$ ) as well as urine DHA levels ( $p < 0.05$ ) there were found significant level dependencies between the 7th and 21st day of the cycle (Tables 3, 4). Further statistical analysis ( $r_{xy}$  - coefficient of correlation) was directed towards correlative relationships: serum DHA  $\rightarrow$  T, serum T  $\rightarrow$  A-DIOL and serum DHA  $\rightarrow$  urine DHA. Significant level dependency of serum DHA and T ( $p < 0.05$ ) was registered, as well as serum T and A-DIOL ( $p < 0.05$ ) on the 21st day of menstrual cycle, while for serum and urine DHA there was not significant level dependency either for the 7th or the 21st day (coefficient of correlation -  $r_{xy}$ ).

Table 3. Dependence of testosterone (T) and androstanediol (A-DIOL) levels in the patients' sera

DHA (µg/dl)		Testosterone (ng/dl)						TOTAL	
		decreased (≤ 17)		physiologic (18 - 22)		increased (≥ 23)			
day		f	%	f	%	f	%	f	%
7th	decreased (≤ 19)	1	2	1	2	8	16	10	20
7th	physiologic (20 - 40)	6	12	7	14	13	26	26	52
7th	increased (≥ 41)	4	8	4	8	6	12	14	28
TOTAL		11	22	12	24	27	54	50	100
21st	decreased (≤19)	2	4	1	2	-	-	3	6
21st	physiologic (20 - 40)	7	4	6	12	18	36	31	62
21st	increased (≥ 41)	3	6	9	18	4	8	16	32
TOTAL		12	24	16	32	22	44	50	100

day 7 of the period:  $X^2 = 3.625$ ; NS

day 21 of the period:  $X^2 = 11.003$ ,  $p < 0,05$

## DISCUSSION

The sex hormone binding globulin (SHBG) levels were not determined due to technical reasons, which does not reduce the value of this study since the unbound T fraction is the only one which is biologically active<sup>1, 26,27</sup>. In healthy women 50-70% of T originates from peripheral androstenedione skin conversion. In 54 % of female subjects there were found elevated serum T levels on the 7th day of the cycle, and in 44% on the 21st day of the cycle. The association in T levels on the 7th day and 21st day correlated with the literature data<sup>28,29</sup>. In female subjects elevated T levels were not found in urine contrary to some other authors<sup>2,3</sup>. DHA is a precursor hormone for C<sub>19</sub> and C<sub>18</sub> steroids. The results did not suggest the presence of significant dependency between serum and urine DHA levels in women with AA. However, the significance of DHA for the studied pathology was confirmed by the analysis of the relationship of serum DHA → T, since DHA acted identically also on the level relation the 7th → 21st day of the menstrual cycle (according to well known α - metabolic

pathway of androgen hormones).

Referring to the metabolism: DHA → androstenedione → T → A-DIOL, and having in mind high serum T levels in the majority of female subjects, it may be supposed that the metabolism is directed towards the level DHA → T in progesterone phase of the cycle. A significant dependency of DHA and T levels on the 21st day was registered. By statistical analysis T was shown as the targeted marker for AA in women, due to the proven level association for the 7th and 21st day of the cycle.

There was noticed a different behavior of individual steroids depending on the cycle phase, on the basis of which it may be concluded that the estrogen phase in female subjects was followed by hormonal dysbalance which in progesterone phase receives its targeted route (there was registered dependency at the level T → A-DIOL in the progesterone phase). This observation suggests the metabolic route of α-series of C<sub>19</sub> steroids in women with AA.

## CONCLUSION

The results indicate that in women with AA the estrogen phase is the one followed by hormonal dysbalance which in progesterone phase receives its targeted route and suggest the possible significant

biological activity of A-DIOL as a peripheral steroid in etiopathogenesis of AA in women. A possible way to prove this hypothesis would be an in vitro study which is unfortunately at present technically not possible to apply as a standardized method.

## REFERENCES

1. Kveder CJ, Gibson M, Krušinski AP. Hirsutism: Evaluation and Treatment. *J Am Acad Dermatol* 1985; 211: 215-25.
2. Apostolakis M, Ludwig E, Voight KD. Testosteron - Oestrogen und Gonadotropen - Ausscheidung bei diffusen unerblicher Alopecia. *Klin Wochr* 1965; 43: 9-12.
3. Ludwig E. Über das endokrine Substrat der diffusen weiblichen (androgenetischen) Alopecie. *Arch Klin Exp Derm* 1966; 227: 468-77.
4. De Villez RL, Dunn J. Female androgenetic alopecia. The 3  $\alpha$ , 17  $\beta$ -androstenediol glucuronide/sex hormone binding globulin ratio as a possible marker for female pattern baldness. *Arch Dermatol* 1986; 122: 1011-6.
5. Schweikert UH, Wilson DJ. Regulation of human hair growth by steroid hormones. I Testosterone metabolism in isolated hairs. *J Clin Endocrinol Metab* 1974; 38: 811-9.
6. Schweikert UH, Wilson DJ. Regulation of human hair growth by steroid hormones. II Androstenedione metabolism in isolated hairs. *J Clin Endocrinol Metab* 1974; 39: 1012-9.
7. Schweikert UH, Milewich, Wilson DJ. Amortization of androstenedione by isolated human hairs. *J Clin Endocrinol Metab* 1975; 40: 413-7.
8. Schweikert UH, Milewich, Wilson DJ. Amortization of androstenedione by cultured human hairs fibroblasts. *J Clin Endocrinol Metab* 1976; 43: 785-95.
9. Farthing GJM, Mattei MA, Edwards WRC, Dawson MA. The relationship between plasma testosterone and dihydrotestosterone concentrations and male facial hair growth. *Br J Dermatol* 1982; 107: 559-64.
10. Schweikert UH, Wilson DJ. Androgen metabolism in isolated human hair roots. In: *Hair research: status and future aspects*, eds: Orfanos EC, Montagna W, Stuttgart G. Springer, Berlin, Heidelberg, New - York, 1981, pp. 210-24.
11. Ebling FJ. Hormonal control of hair growth. *ibidem*, pp. 195-204.
12. Bassas E. Genetic and androgens in male pattern alopecia. *Physiopathologic basis of hair graft*. *ibidem*, pp. 686-90.
13. Dawber RPR. Disorders of hair and nails in: *Scientific basis of dermatology - a psychological approach*. Eds. Thody J, Friedman SP, Churchill Livingstone, Edinburgh, 1986, pp. 330-48.
14. Strauss SJ. Hormones and the pilosebaceous apparatus. In: *Hair research: status and future aspects*, eds: Orfanos EC et al, Springer, Berlin, 1981, pp. 223-8.
15. Adachi K, Kano M. Adenyl-cyclase in human hair follicle: Its inhibition by dihydrotestosterone *Biochem Biophys Res Commun* 1970; 41: 884-90.
16. Sansone-Bazzano G, Reisner MR, Bazzano G. Conversion of testosterone - 1,2<sup>3H</sup> to androstenedione<sup>3H</sup> in the isolated hair follicle in men. *J Clin Endocrinol Metab* 1972; 34: 512-5.
17. Rook A. Endocrinal influence of hair growth. *Br J Dermatol* 1965; 77: 609-14.
18. Ludwig E. Classification of the types of androgenetic alopecia (common baldness) occurring in the female sex. *Br J Dermatol* 1977; 94: 247-54.
19. Bardin CW, Lipset MB. Testosterone and androstenedione blood productions rates in normal women with idiopathic hirsutism or polycystic ovaries. *J Clin Invest* 1967; 46: 891-901.
20. Price VH. Testosterone metabolism in the skin. *Arch Dermatol* 1975; 111: 1496-502.
21. Rosenfield RL, Ehrlich EN, Clary RE. Adrenal and ovarian contributions for the elevated free plasma androgen level in hirsute women. *J Clin Endocrinol Metab* 1972; 34: 92-8.
22. Zaun H. Untersuchungen über den Einfluss

antikonzeptiver Zweiphasen - hormonpräparate auf das Wachstum der Kopfhaare. *Arch Klin Exp Derm* 1970; 238: 197-206.

23. Cormia F. Alopecia from oral contraceptives. *JAMA* 1967; 201: 635-7.

24. Horton R, Neiseler J. Plasma androgens in patients with polycystic ovarian disease. *J Clin Endocrinol Metab* 1968; 28: 479-83.

25. Ivanović S. Ispitivanje androsterona i etioholanolona kod benignih i malignih tumora dojke. *Doktorska disertacija, Beograd* 1977

26. Baird D, Horton R, Langcope JF. Steroid dynamics under steady state conditions. *Recent Prog Horm Res* 1969; 25: 611-29.

27. Padridge WM. Transport of protein bound hormones into tissues in vitro. *Endocrinol Rev* 1981; 2: 103-6.

28. Cipriani R, Puzza G, Foresta C, Veller Fornasa C, Peserico A. Sex hormone-binding globulin and saliva testosterone levels in men with androgenetic alopecia. *Br J Dermatol* 1983, 109: 249-52.

29. Mortimer CH, Rushton H, James. Effective medical treatment of common baldness in women. *Clin Exp Dermatol* 1984; 914: 342-50.

#### AUTHOR'S ADDRESSES

Martinović Nevenka, MD PhD, assistant professor of dermatology, Institute for skin and venereal diseases, Pasterova 2, 11000 Beograd, Yugoslavia

Mićić Jovan, MD PhD, professor of endocrinology, Institute of endocrinology, Doktora Subotića 16, Beograd, Yugoslavia

Ivanović Slavica, MD PhD, endocrinologist, Institute of oncology, Pasterova 6, Beograd, Yugoslavia

Krunić Aleksandar MD, PhD, assistant professor of dermatology, Institute for skin and venereal diseases, Pasterova 2, Beograd, Yugoslavia